The overall variety of confirmed COVID-19 circumstances all over the world is 18,317,520 -an enhance of greater than 1.7 million since final week.
The worldwide loss of life toll from COVID-19 surpassed 700,000 on Wednesday, with america, Brazil, India and Mexico main the rise in fatalities.
Almost 5,900 persons are dying each 24 hours from COVID-19 on common, in line with calculations primarily based on information from the previous two weeks. That works out to 247 folks per hour, or one individual each 15 seconds!
America and Latin America are the brand new epicentres of the pandemic, each are struggling to curb the unfold of the virus. The US authorities’s high infectious illness knowledgeable, Dr Anthony Fauci, yesterday stated states with excessive coronavirus case counts ought to rethink imposing lockdown restrictions.
The coronavirus was initially slower to achieve Latin America, which is residence to about 640 million folks, than a lot of the world. However officers have since struggled to regulate its unfold due to the area’s poverty and densely packed cities.
Novavax’s Covid-19 vaccine exhibits promising immune response, early information present.
A possible Covid-19 vaccine from the biotech firm Novavax confirmed a promising immune response in a small, early trial, however not with out a excessive charge of largely delicate negative effects.
The outcomes, revealed Tuesday, are the most recent encouraging signal within the international effort to develop a vaccine for the novel coronavirus, which has killed practically 700,000 folks all over the world. However the Novavax information, very similar to outcomes not too long ago revealed by Moderna and AstraZeneca, are too preliminary to attract any conclusions about how nicely the vaccine would possibly defend towards Covid-19, consultants stated.
“It’s a small variety of folks in every arm, and the research wasn’t designed to show efficacy, that are the usual caveats for a Section 1 trial,” stated Edward Belongia, an epidemiologist and vaccine researcher on the Marshfield Clinic Analysis Institute in Wisconsin. “Having stated that, it appears to be like very promising — a minimum of as promising if no more so than the opposite vaccines we’ve checked out.”